Drug Profile

CYT 1010

Alternative Names: CYT 1010; Cyt1010

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tulane University
Developer Cytogel
Class Analgesics; Peptides
Mechanism of Action Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Pain

Highest Development Phases

Phase II Acute pain
No development reported Pain

Most Recent Events

28 Apr 2025 No recent reports of development identified for preclinical development in Acute pain in USA (PO)
28 Apr 2025 No recent reports of development identified for preclinical development in Pain in USA (PO)
05 Mar 2021 Phase-II clinical trials in Acute pain in USA (IV), prior to March 2021 (Cytogel Pharma pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com